hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
POLB 001 patent portfolio strengthened through granting of US patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
hVIVO saw record revenues for another year in 2022 as demand for its human challenge trials accelerated. And 2023 could see further gains.
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the “Notification Letter”)
When a UK biotech firm starts to show promise, they set sail across the Atlantic. Investors can’t blame them.
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update which reflects lower than expected revenue,